Predictive Drug Safety highlights innovative preclinical strategies that are underway, for predicting drug-induced organ toxicities early and accurately.

Building on the success of last year, Cambridge Healthtech Institute's Second Annual Targeting Histone Methyltransferases conference, September 24-25 in Boston, is the preeminent event for HMTi development, gathering a diverse cross-section of academi

Sub-visible particles present in these biopharmaceutical products are a product quality attribute and a potential patient safety concerns yet to be fully explored. Early and consistent particle detection, quantitation and control throughout the product life cycle of these drugs from development to commercial lot release is critical in mitigating any concerns. This requires appropriate analytical methods which can be applied to biopharmaceuticals across a large variety of protein concentrations and modes of administration. This DVD will cover strategies to utilize complementary methods and techniques at different phases of product development.

Escherichia coli has proven its worth as a protein expression platform. Currently, E.coli is not viewed so much as an ‘alternative’ platform, but as a viable choice for achieving high-level expression of human genes and proteins at a reasonable cost.

Escherichia coli has proven its worth as a protein expression platform. Currently, E.coli is not viewed so much as an ‘alternative’ platform, but as a viable choice for achieving high-level expression of human genes and proteins at a reasonable cost.